In HER2+ tumors undergoing neoadjuvant chemotherapy, the persistence of microcalcifications raises questions: they often represent residual DCIS, which must be surgically removed, even in the absence of residual invasive disease [30]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.